Navigation Links
Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype
Date:10/15/2010

CARLSBAD, Calif., Oct. 15 /PRNewswire/ -- Shrink Nanotechnologies, Inc. ("Shrink") (OTC Bulletin Board: INKN), an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering – the StemDisc450™, a high-yield, low cost, patent-pending cell culturing biomedical research tool.  Shrink expects to begin offering this product for sale in the latter part of 2010.

(Photo:  http://photos.prnewswire.com/prnh/20101015/LA83329)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20101015/LA83329)

"Tissue engineering and cell culturing are high growth areas of the biotechnology field.  This trend is being fueled as the idea of 'personalized medicine' – or 'therapeutics and treatments made for you' - becomes a reality.  And as the personalized medicine movement grows, biotech and pharmaceutical companies are focusing on the promise of novel research, especially new cellular-based therapies, to help combat cancer, spinal cord injuries, diabetes, Parkinson's and Alzheimer's disease, and many more.  StemDisc is a platform for Shrink to offer a growing suite of products that will address an important spectrum of the needs within cellular and tissue engineering technologies and tools," Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

"We have started field testing of our first StemDisc450 prototypes, and we anticipate being able to show time lapse videos of this product performing, and actually developing HESCs (human embryonic stem cells) and IPSCs (induced pluripotent stem cells)," added Baum. "Shrink is exploring opportunities with established stem cell R&D companies for potential strategic partnerships for the sale and marketing of StemDisc™ products. Our primary target market is the more than 3,000 stem cell research labs and 15,000 biomedical laboratories operating in the United States."

About StemDiscStemDisc is designed to improve embryoid body (EB) formation of stem cells at a higher rate and efficiency over current EB formation methods.  The platform can be used to grow and differentiate human and animal single cells, human embryonic stem cells (HESCs) and induced pluri-potent stem cells (IPSCs). Versions of StemDisc's unique honeycomb-like well will be offered in different diameter and depth depending on the type of cell and application. Each round bottom "microwell" is capable of making 800 to 1,000 EBs, increasing the flexibility of use for researchers to achieve optimum EB formation with high reliability compared to legacy methods.  A unique feature of the StemDisc product line is the optical transparency of the surface that the cells rest in.  The StemDisc polymer offers amazing transparency, providing the cell biologist with the ability to see more of what she is doing as she completes her research.  StemDisc's five micron walls between microwells virtually assure a clean transfer of the biological material into a well – in a few easy steps, helping to further lower costs and accelerate the time to publish results of potentially life-saving studies.  If you are interested in receiving more information about StemDisc, please contact us by visiting www.shrinknano.com.

About Shrink Nanotechnologies, Inc.Shrink Nanotechnologies, Inc. is a one-of-a-kind FIGA™ organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. The Company's unique NanoShrink™ material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries. For more information, please visit www.shrinknano.com.

See also:

http://www.shrinksolar.com/blog/

http://www.shrinknano.com/products/product-tools

http://www.shrinknano.com/products/product-diagnostics

http://www.shrinknano.com/tech

http://www.shrinknano.com/tr35-a-children%E2%80%99s-toy-inspires-a-cheap-easy-production-method-for-high-tech-diagnostic-chipsContact:For Shrink NanotechnologiesMark L. Baum, Esq.760-804-8844 x205(Logo:  http://photos.prnewswire.com/prnh/20101015/SHRINKLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20101015/SHRINKLOGO)

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink's ability to obtain additional financing and to build and develop markets for Shrink's biotechnology technologies and products. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink's success are more fully disclosed in Shrink's most recent public filings with the U.S. Securities and Exchange Commission.


'/>"/>

SOURCE Shrink Nanotechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
2. Novel CU-Boulder technique shrinks size of nanotechnology circuitry
3. The nano world of Shrinky Dinks
4. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
5. Touch Bionics unveils innovative partner and reimbursement programs at AOPA
6. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
7. FBI unveils science of anthrax investigation
8. Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research
9. McMaster University unveils worlds most advanced microscope
10. BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service
11. Video: Insulet Unveils Video Contest for OmniPod Users
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... As part of an ongoing ... and expanding its LATAM network and logistics capabilities. Enhancements have been made ... clinical trial projects. , The expansion will provide unmatched clinical trial logistics services ...
(Date:4/27/2016)... Boston (PRWEB) , ... April 27, 2016 , ... ... driven by semantic web technology, today announced that it has been named to The ... life sciences, financial services and other markets, Cambridge Semantics serves the needs of end ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee ... Chuck has been a volunteer member of Committee since 1987. Since then, he ... of directors and treasurer and was chairman for both the program and exposition committees. ...
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
(Date:3/3/2016)... NOTTINGHAM, England and DE SOTO, ... , U.S.-based Stroke Detection Plus® to offer Oncimmune,s ... the risk assessment and early detection of lung cancer ... include large employers, unions and individuals. --> ... employers, unions and individuals. --> Oncimmune, a ...
Breaking Biology News(10 mins):